Three compounds — tariquidar, terfenadine, and zinc pyrithione — blocked the conversion of proinflammatory fascia fibroblasts into myofibroblast precursor cells in mouse skin explants, a commentary in the Journal of Investigative Dermatology reports. The piece appeared online October 7, 2026.

Christopher A. McCulloch wrote the commentary alongside the original study "Fascia-integrated functional mapping of ion channels promotes scar-tapered repair" by Ruiji Guo and colleagues, including senior author Yuval Rinkevich, posted July 9, 2026.

What did the compound screen identify?

Guo et al. ran a targeted compound library against fascia tissue to find ion channel inhibitors that prevent the deformation driving scar formation. The screen flagged 7 ion channel classes with potential therapeutic value for contracture prevention and 19 ion channel types that produced no effect on fibroblast conversion.

Three leads — TQR, TFD, and ZPT — blocked the proinflammatory-to-myofibroblast transition in the explant assays. Zinc pyrithione, a copper ionophore, inhibited fascia contraction, shrank scar size, and improved collagen fiber organization in the mouse model.

Why does the mechanism matter for scarring?

Scar formation depends on fascia-resident fibroblasts shifting into contractile myofibroblasts that pull wound edges together. McCulloch framed the advance in mechanistic terms:

"The authors provide novel insights into the mechanisms by which fascia tissue deformation leading to the conversion of resting fibroblasts to myofibroblasts is regulated, an important process that occurs in the healing of wounds and the formation of scars."

The work extends prior studies from Rinkevich's group, including a 2019 Nature paper on fascia-mediated repair of deep wounds and a 2023 Nature paper on CD201+ fascia progenitors that choreograph injury repair.

How translatable are the mouse findings?

The commentary flags clear translational gaps. Mouse skin differs structurally from human skin, and the assays used ex vivo explants only. McCulloch described the paper's "striking originality" and "very solid demonstration" of ion channel importance, while leaving open questions for future work.

Specific caveats raised in the commentary:

• Several screened compounds act through more than one mechanism, complicating attribution to any single ion channel
• Pathway analyses have not yet pinned down the precise signaling involved
• Human skin fascia architecture remains untested in this system

What is known about the three lead compounds?

The cited references describe terfenadine as a histamine H1 receptor antagonist previously studied for STAT3-mediated apoptosis induction in HCT116 colorectal cancer cells. Tariquidar and zinc pyrithione appear in the screening panel but receive no further characterization in the available excerpts. McCulloch declared no conflict of interest and disclosed no use of AI or large language models in manuscript preparation.

What comes next?

McCulloch called for refined assays and more detailed pathway analyses to confirm which ion channels drive the antifibrotic effect. Subsequent studies will need to test these candidates in human skin or organotypic models before any scar-reduction therapy can advance toward clinical development. DOI: 10.1016/j.jid.2026.08.006.